Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18767244 | 0.80 | SMN1; SMN2 (0.44) | ALDH1A1HSD17B10TDP1S1PR1MAPT | |
| SCHEMBL21469881 | 0.77 | PTGS2 (0.41) | ALDH1A1S1PR2 | |
| SCHEMBL17398022 | 0.77 | LCK (0.43) | ALDH1A1HSD17B10TDP1S1PR2S1PR1 | |
| SCHEMBL218559 | 0.76 | ALDH1A1 (0.53) | ALDH1A1HSD17B10TDP1CYP3A4CA1 | |
| SCHEMBL724036 | 0.73 | TDP1 (0.46) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL184464 | 0.72 | TSHR (0.47) | ALDH1A1HSD17B10TDP1CYP3A4TSHR | |
| SCHEMBL3452145 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1MAPTKMT2A | |
| SCHEMBL17397930 | 0.72 | SMN1; SMN2 (0.34) | ALDH1A1S1PR2S1PR1MAPT | |
| SCHEMBL29273586 | 0.72 | CA12 (0.52) | ALDH1A1S1PR2MEN1KMT2ATSHR | |
| SCHEMBL20241140 | 0.70 | TSHR (0.44) | ALDH1A1HSD17B10TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133191-A1 | NOVEL SULFONAMIDES OR SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2025-06-26 | — | — | WO | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-118344342-A | Substituted polyaromatic ring derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885HSD17B10 1483/4885TDP1 3069/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885HSD17B10 1483/4885TDP1 3069/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885HSD17B10 1483/4885TDP1 3069/4885 |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | ALDH1A1 4498/4885HSD17B10 4247/4885TDP1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.